Table 6.

Summary of recommendations and judgments

Intervention	Benefit	Risk	Cost*	Access	Evidence†	Recommendation
Pharmacological therapy for COVID-19
Hydroxychloroquine (or chloroquine)	Small or neglectable	Important	Low	Good‡	Low	Against routine use (weak)
Hydroxychloroquine (or chloroquine) + azithromycin	Small or neglectable	Important	Low	Good‡	Very low	Against routine use (weak)
Lopinavir/ritonavir	Small or neglectable	Moderate	Low	Limited§	Low	Against routine use (weak)
Oseltamivir	Small or neglectable	Small or neglectable	Low	Good‡	Very low	Against the use (strong)
Tocilizumab	Small or neglectable	Moderate	High	Limited§	Very low	Against routine use (weak)
Corticosteroids	Small or neglectable	Important	Low	Good‡	Very low	Against routine use (weak)
Heparin - anticoagulant dose	Small or neglectable	Important	Moderate	Good‡	Very low	Against routine use (weak)
Conditions associated with COVID-19
Oseltamivir (suspected influenza in severe cases or risk factors)	Moderate	Small or neglectable	Low	Good‡	Very low	Favorable to use (weak)
Prophylactic heparin doses (hospitalized patients)	Moderate	Small or neglectable	Low	Good‡	Very low	Favorable to use (strong)
Antibiotics (prophylactic)	Small or neglectable	Small or neglectable	Low	Good‡	Very low	Against the use (weak)
Antibiotics (suspected bacterial infection)	Important	Small or neglectable	Low	Good‡	Not assessed	Favorable to use

Qualitative assessment, considering public and complementary health systems, based on prices according to the Painel de Preços do Ministério da Economia (Ministry of Economy Prices Panel), Banco de Preços em Saúde (Health Products Prices Data Bank), Tabela Câmara de Regulação do Mercado de Medicamentos (Table from the Medicines Price Regulation Chamber) and usual market prices;

^†evidence assessed according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE);

^‡good availability in the Brazilian context, either products or use experienced professionals.